Skip to main content Skip to main content

Childhood, Regulation, and Neuroscience

In the last decade, our understanding of childhood development, mood regulation, and attachment has blossomed from discoveries in the field of neuroscience. We now know a lot about how the regulatory capacity develops in children and the relationship to a…

Credits: AMA PRA Category 1 Credits™ (1 hour)

Price: $47

Faculty: Lisa Dion, MA, LPC
Learn More

Creating an Inspired Integrative Psychiatric Practice

Practicing medicine should be inspiring, a career full of opportunities for growth and learning. Many physicians struggle to maintain the spark of excitement about going to work, or even worse, burn out. In this course, you will get a fresh…

Credits: AMA PRA Category 1 Credits™ (1 hour)

Price: $47

Faculty: Keith Kurlander, MA, LPC
Learn More

Exercise Recommendations for Symptom Clusters

It’s common sense that exercise can keep the doctor away. But, are you up-to-date on the research about why exercise is so important and the various exercise routines that are better indicated for certain types of mental health conditions? In…

Credits: AMA PRA Category 1 Credits™ (1 hour)

Price: $47

Faculty: Jen Pilotti, MA
Learn More

Functional Medicine Approaches to Sleep

Patients with insomnia regularly show up looking for help in the clinics of family medicine, internal medicine, pediatrics, psychiatry, surgery, oncology, neurology, even dermatology.   Insomnia is a major problem that is often difficult to treat effectively. Even the scientific…

Credits: AMA PRA Category 1 Credits™ (1 hour)

Price: $47

Faculty: Ashwin Mehta, MD
Learn More

Gut-Brain and the Microbiome

Unfortunately, most medical providers have not been educated about the latest research on the gut-brain axis, and the relationship between gut health and mental health. In recent years, research has demonstrated that microbiome issues and gut inflammation can drive psychiatric…

Credits: AMA PRA Category 1 Credits™ (1 hour)

Price: $47

Faculty: Chris Lowry, PhD
Learn More

Integrative Treatment for Trauma and Complex PTSD

1 in 6 adults have four or more Adverse Childhood Experiences “ACEs.” Even more startling, the CDC’s website states, “preventing ACEs could reduce the number of people with depression by as much as 44%. ACEs do not predetermine an individual's…

Credits: AMA PRA Category 1 Credits™ (1 hour)

Price: $47

Faculty: Arielle Schwartz, PhD
Learn More

Introduction to Root Causes – HPA Axis

Chronic stress and HPA axis dysregulation are often present in mental health disorders but are commonly overlooked. Conventional ways of diagnosing cortisol irregularities simply fall short when assessing adrenal insufficiency. There is a wide range of adrenal function between the…

Credits: AMA PRA Category 1 Credits™ (1 hour)

Price: $47

Faculty: Will Van Derveer, MD
Learn More

Ketamine Assisted Psychotherapy: Treatment Resistant Depression

Psychedelic-assisted psychotherapy has received great interest in research, particularly in the last decade. Currently, Ketamine-Assisted Psychotherapy is the only legal treatment available. Are you wondering which patients with treatment resistant depression (TRD) may benefit from ketamine treatment? In this course,…

Credits: AMA PRA Category 1 Credits™ (1 hour)

Price: $47

Faculty: Will Van Derveer, MD
Learn More

Frederick Barrett is a cognitive neuroscientist with training in behavioral pharmacology, and the Associate Director of the Johns Hopkins Center for Psychedelic and Consciousness Research. Dr. Barrett has been conducting psychedelic research at Johns Hopkins University since 2013, and his research in healthy participants and in patients with mood and substance use disorders focuses on the psychological and neurological mechanisms underlying the enduring therapeutic and other effects of psychedelic drugs. In 2017, he received an NIH “R03” grant as Principal Investigator to investigate biological mechanisms of psilocybin effects, the first federally funded research since the 1970s administering a classic psychedelic to people with psychedelic effects as the primary focus. He has developed measures of subjective effects of psychedelic drugs, and has also published first-in-human studies characterizing the acute and enduring effects of psilocybin on the brain. He is currently leading clinical trials to investigate the use of psilocybin to treat patients with major depressive disorder and co-occurring alcohol use disorder, and he is leading a number of ongoing studies aimed at better understanding the psychological, biological, and neural mechanisms underlying therapeutic efficacy of psychedelic drugs.

Will Van Derveer, MD is co-founder of Integrative Psychiatry Institute (IPI), along with friend and colleague Keith Kurlander, MA. He co-created IPI as an expression of what he stands for. First, that anyone can heal, and second that we medical providers must embrace our own healing journeys in order to fully command our potency as healers.

Dr. Van Derveer spent the last 20 years innovating and testing a comprehensive approach to addressing psychiatric challenges which transcends the conventional model he learned in medical school at Vanderbilt University and residency at University of Colorado, while deeply engaging his own healing path.

He founded the Integrative Psychiatric Healing Center in in 2001 in Boulder, CO, where he currently practices. Dr. Van Derveer regards unresolved emotional trauma as the most significant root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass. In addition to his clinical work and teaching, he was co-investigator in 2016 a Phase II randomized clinical trial, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). He continues to support this protocol, now in a Phase III clinical trial under break-through designation by FDA.

Dr. Van Derveer is a diplomate of the American Board of Integrative and Holistic Medicine (ABoIHM) since 2013, and he was board certified in the first wave of diplomates of the new American Board of Integrative Medicine (ABIM) in 2016.